ChemoCentryx now owns the drug’s rights, including for inflammatory bowel disease, thus ending the seven-year strategic alliance between the two companies. GSK initially paid $63.5 million to ChemoCentryx to study treatments for IBD.
Vercirnon failed to meet GSK’s primary and secondary endpoint in the first of four Phase III trials; the drug neither brought an improved clinical response nor clinical remission.
More Articles on Gastroenterology:
“S” or “C” Corporation for Your Gastroenterology Practice: Maximize Tax Deductions by Using Both!
Colonoscopy Could Prevent 40% Colon Cancer Cases, Study Says
Gastro Florida Practice Names Mark O’Neill as CEO
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
